gemcitabine + oxaliplatin + lenvatinib + PD-1 inhibitor

This is a multi-agent combination regimen consisting of four drugs with distinct mechanisms of action, used primarily in oncology research and clinical trials. - **Gemcitabine** is a nucleoside analog (antimetabolite) that inhibits DNA synthesis, leading to apoptosis in rapidly dividing tumor cells. - **Oxaliplatin** is a platinum-based chemotherapeutic agent that forms DNA adducts, disrupting DNA replication and transcription. - **Lenvatinib** is an oral small molecule tyrosine kinase inhibitor targeting multiple receptors including VEGFR, FGFR, PDGFRα, RET, and KIT; it inhibits angiogenesis and tumor cell proliferation. - **PD-1 inhibitors** are monoclonal antibodies that block the programmed death 1 (PD-1) immune checkpoint on T cells (such as pembrolizumab or nivolumab), enhancing anti-tumor immune responses. This combination leverages cytotoxic chemotherapy (gemcitabine/oxaliplatin), targeted therapy (lenvatinib), and immunotherapy (PD-1 inhibitor) for synergistic anti-cancer effects. It has been explored in various advanced solid tumors but does not have a unique brand name or established fixed-dose formulation.